Signifor (pasireotide), an approved therapy for Cushing’s disease, has shown promise as a long-term treatment for some patients with the disease, according to results of an extension study of a Phase 3 clinical trial (NCT00434148). These findings were published recently…
News
Aggressive adrenocortical carcinomas differ from tumors linked to Cushing’s syndrome in the density of blood and lymph vessels, according to a research team at Portugal’s University of Porto. Their study, “Angiogenesis and Lymphangiogenesis in the Adrenocortical Tumors,” appeared in the journal Pathology & Oncology Research. It offers insights into the…
News
Researchers Identify Gene Mutations Likely Promoting Pituitary Tumor Growth in Cushing’s Disease
Mutations in a gene called CABLES1 might contribute to pituitary tumor growth in people with Cushing’s disease, according to a study that suggests the gene normally acts as a pituitary tumor suppressor. The study, “Loss-of-function mutations in the…
Five European countries have agreed to Verona Pharma’s plan to begin enrolling patients in a Phase 2b clinical trial of RPL554 as a maintenance treatment for chronic obstructive pulmonary disease, or COPD. The trial will be conducted in the United Kingdom, Germany, Romania, Bulgaria, and the Czech Republic. Verona expects to start…
The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently approved Daxas (roflumilast), developed by AstraZeneca, as a treatment for chronic obstructive pulmonary disease (COPD). The new indication could potentially benefit about 122,000 adults in the U.K. who are estimated to be eligible to receive Daxas, according…
The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health has granted $10 million to the McDonnell Genome Institute at Washington University to investigate and identify genes associated with chronic obstructive pulmonary disease (COPD) and other lung disorders in people from diverse ethnic backgrounds. Results of…
Recent Posts
- Korlym improves results for diabetes patients taking GLP-1 drugs
- New ‘Everyday Advocacy’ initiative supports Cushing’s syndrome care
- Intersecting identities: The similarities in being queer and chronically ill
- Sonic Hedgehog pathway may be target in Cushing’s disease
- Incidental adrenal mass leads to man’s Cushing’s diagnosis: Report
- What a Cushing’s disease flare-up looks like for me
- Rare case study details double Cushing’s syndrome/disease diagnosis
- Quality of life improvements vary widely after Cushing’s disease surgery
- How I explain Cushing’s disease to children
- Asedebart for Cushing’s disease granted orphan drug status in Japan